Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00093873

Enrollment

Registered

2004-10-08

Start date

2003-07-31

Completion date

2006-12-31

Last updated

2013-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors

Keywords

Cancer, antiangiogenesis, Solid Tumors

Brief summary

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Interventions

DRUGAnti-angiogenesis

Anti-angiogenesis

DRUGAMG 706

Anti-angiogenesis

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicity	Cycle 1

Secondary

Measure	Time frame
Dose selection	Study completion

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026